This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Aug 24;377(8):787-8.

doi: 10.1056/NEJMc1708587.

Evolocumab in Patients with Cardiovascular Disease

Marc S Sabatine^{1

2}, Robert P Giugliano¹, Terje R Pedersen³

Affiliations

Affiliations

¹ Brigham and Women’s Hospital, Boston, MA
² msabatine@partners.org
³ Oslo University Hospital, Oslo, Norway

PMID: 28834471
DOI: 10.1056/NEJMc1708587

Free article

Comment

Evolocumab in Patients with Cardiovascular Disease

Marc S Sabatine et al. N Engl J Med. 2017.

Free article

. 2017 Aug 24;377(8):787-8.

doi: 10.1056/NEJMc1708587.

Authors

Marc S Sabatine^{1

2}, Robert P Giugliano¹, Terje R Pedersen³

Affiliations

¹ Brigham and Women’s Hospital, Boston, MA
² msabatine@partners.org
³ Oslo University Hospital, Oslo, Norway

PMID: 28834471
DOI: 10.1056/NEJMc1708587

No abstract available

PubMed Disclaimer

Comment on

Evolocumab in Patients with Cardiovascular Disease.
Koskinas KC, Windecker S. Koskinas KC, et al. N Engl J Med. 2017 Aug 24;377(8):786. doi: 10.1056/NEJMc1708587. N Engl J Med. 2017. PMID: 28834472 No abstract available.
Evolocumab in Patients with Cardiovascular Disease.
Nunes JPL. Nunes JPL. N Engl J Med. 2017 Aug 24;377(8):787. doi: 10.1056/NEJMc1708587. N Engl J Med. 2017. PMID: 28834473 No abstract available.
Evolocumab in Patients with Cardiovascular Disease.
García de Tena J, Morales-Ortega A, Pindao-Quesada G. García de Tena J, et al. N Engl J Med. 2017 Aug 24;377(8):785. doi: 10.1056/NEJMc1708587. N Engl J Med. 2017. PMID: 28836418 No abstract available.
Evolocumab in Patients with Cardiovascular Disease.
Naci H, Mehra MR. Naci H, et al. N Engl J Med. 2017 Aug 24;377(8):785-6. doi: 10.1056/NEJMc1708587. N Engl J Med. 2017. PMID: 28836419 No abstract available.
Evolocumab in Patients with Cardiovascular Disease.
Redberg RF, Prasad V. Redberg RF, et al. N Engl J Med. 2017 Aug 24;377(8):786-7. doi: 10.1056/NEJMc1708587. N Engl J Med. 2017. PMID: 28836420 No abstract available.

Similar articles

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Sabatine MS, et al. N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15. N Engl J Med. 2015. PMID: 25773607 Clinical Trial.
Evolocumab in Patients with Cardiovascular Disease.
Nunes JPL. Nunes JPL. N Engl J Med. 2017 Aug 24;377(8):787. doi: 10.1056/NEJMc1708587. N Engl J Med. 2017. PMID: 28834473 No abstract available.
Evolocumab in Patients with Cardiovascular Disease.
Koskinas KC, Windecker S. Koskinas KC, et al. N Engl J Med. 2017 Aug 24;377(8):786. doi: 10.1056/NEJMc1708587. N Engl J Med. 2017. PMID: 28834472 No abstract available.
Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
Henry CA, Lyon RA, Ling H. Henry CA, et al. Vasc Health Risk Manag. 2016 Apr 19;12:163-9. doi: 10.2147/VHRM.S82387. eCollection 2016. Vasc Health Risk Manag. 2016. PMID: 27143910 Free PMC article. Review.
Effects of Evolocumab on Cardiovascular Events.
Mikhail N. Mikhail N. Curr Cardiol Rev. 2017;13(4):319-324. doi: 10.2174/1573403X13666170918165713. Curr Cardiol Rev. 2017. PMID: 28925859 Free PMC article. Review.

See all similar articles

Cited by

Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice?
Ferrières J, Bataille V, Puymirat E, Schiele F, Simon T, Danchin N; FAST-MI investigators. Ferrières J, et al. Clin Cardiol. 2020 Nov;43(11):1260-1265. doi: 10.1002/clc.23437. Epub 2020 Jul 28. Clin Cardiol. 2020. PMID: 32720384 Free PMC article.
Management of Hyperlipidemia in Very High and Extreme Risk Patients in Croatia: an observational study of treatment patterns and lipid control.
Pintarić H, Knezović Florijan M, Bridges I, Steiner R, Zaputović L, Miličić D. Pintarić H, et al. Acta Clin Croat. 2020 Dec;59(4):641-649. doi: 10.20471/acc.2020.59.04.10. Acta Clin Croat. 2020. PMID: 34285435 Free PMC article.
Association of MPO levels with cardiometabolic disease stratified by atherosclerotic cardiovascular risk and intensity of therapy in a workforce population.
Iakoubova OA, Haji-Sheikhi F, Louie JZ, Rowland CM, Arellano AR, Bare LA, Birse CE, Penn MS. Iakoubova OA, et al. Sci Rep. 2025 Apr 10;15(1):12244. doi: 10.1038/s41598-025-89373-7. Sci Rep. 2025. PMID: 40210927 Free PMC article.
Disconcordance between ESC prevention guidelines and observed lipid profiles in patients with known coronary artery disease.
Dykun I, Wiefhoff D, Totzeck M, Al-Rashid F, Jánosi RA, Rassaf T, Mahabadi AA. Dykun I, et al. Int J Cardiol Heart Vasc. 2018 Dec 28;22:73-77. doi: 10.1016/j.ijcha.2018.12.004. eCollection 2019 Mar. Int J Cardiol Heart Vasc. 2018. PMID: 30603665 Free PMC article.
Familial Hypercholesterolaemia in a Bulgarian Population of Patients with Dyslipidaemia and Diabetes: An Observational Study.
Tankova T, Elenkova A, Robeva R, Dimova R, Borissova AM, Olszewski A, Lachev V, Petkova R. Tankova T, et al. Diabetes Ther. 2020 Feb;11(2):453-465. doi: 10.1007/s13300-019-00748-2. Epub 2020 Jan 2. Diabetes Ther. 2020. PMID: 31898083 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information